S. Williams

发表

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

L. Gordon, J. Winter, S. Singhal, 2007, Bone Marrow Transplantation.

Paradoxical relationship between acetylator phenotype and amonafide toxicity

R. Schilsky, M. Ratain, R. Mick, 1991, Clinical pharmacology and therapeutics.

Global protein synthesis in human trophoblast is resistant to inhibition by hypoxia.

N. Illsley, S. Zamudio, Shauna F. Williams, 2012, Placenta.

A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.

E. Shpall, T. Shea, G. Long, 1999, Blood.

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

A. Polliack, Y. Ilan, H. Golomb, 1991, Leukemia & lymphoma.

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.

R. Mick, J. Bitran, S. Williams, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells.

M. Loudovaris, W. Lee, J. Bender, 1996, Cytometry.

Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial

K. Cornetta, B. Burtness, D. Krause, 2000, Bone Marrow Transplantation.

Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach.

E. Barker, J. Richards, H. Golomb, 1990, Bone marrow transplantation.

Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1

J. Copland, R. Smallridge, B. Haugen, 2006, Oncogene.

Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.

M. Ratain, M. Egorin, S. Ackland, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HYPERSENSITIVITY REACTION TO HIGH‐DOSE CYTARABINE

R. Larson, S. Williams, 1989, British journal of haematology.

Source of stem cell rescue: bone marrow versus peripheral blood progenitors.

R. Mick, S. Williams, T. Zimmerman, 1993, Journal of hematotherapy.

The staging of non-Hodgkin's lymphomas.

H. Golomb, J. Moormeier, S. Williams, 1990, Seminars in oncology.

Defining a therapeutic dose of peripheral blood stem cells.

L. To, L. Schwartzberg, J. Bender, 1992, Journal of hematotherapy.

Large-scale selection of CD34+ peripheral blood progenitors and expansion of neutrophil precursors for clinical applications.

M. Loudovaris, W. Lee, S. Smith, 1996, Journal of hematotherapy.

Modulation of vinblastine resistance with cyclosporine: A phase I study

R. Schilsky, M. Ratain, R. Mick, 1993, Clinical pharmacology and therapeutics.

Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests.

R. Mick, W. Lee, J. Bender, 1995, Bone marrow transplantation.

High‐dose, multiple‐alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non‐small cell lung cancer

H. Golomb, J. Bitran, P. Hoffman, 1989, Cancer.

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

T. Zimmerman, S. Williams, D. Grinblatt, 1998, Cancer.

Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation.

L. To, W. Lee, S. Myers, 1992, Bone marrow transplantation.

Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.

M. Ratain, R. Larson, L. Platanias, 1994, Leukemia & lymphoma.

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.

J. Bitran, S. Williams, 1989, Hematology/oncology clinics of North America.

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.

P. van Vlasselaer, F. Valone, S. Williams, 2000, Cytotherapy.

Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature

D. Variakojis, S. Williams, R. Veerappan, 2007, Bone Marrow Transplantation.

High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas.

R. Mick, J. Moormeier, S. Williams, 1990, Seminars in oncology.

Peripheral blood stem cell mobilization after stem cell factor or G-CSF treatment: rapid enrichment for stem and progenitor cells using the CEPRATE immunoaffinity separation system.

S. Heimfeld, K. McGuire, S. Williams, 1992, Transplantation proceedings.

Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.

M. Ratain, S. Williams, K. E. Choi, 1989, Cancer research.

Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.

R. Schilsky, J. Ultmann, S. Williams, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation

M. Crump, J. Nabholtz, A. Miller, 2000, Bone Marrow Transplantation.

High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.

D. Hallahan, A. Mundt, S. Williams, 1997, International journal of radiation oncology, biology, physics.

The staging of Hodgkin's disease.

H. Golomb, J. Moormeier, S. Williams, 1989, Hematology/oncology clinics of North America.

High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.

R. Mick, S. Myers, S. Williams, 1994, Bone marrow transplantation.

The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.

R. Schilsky, B. Samuels, J. Ultmann, 1988, Cancer investigation.

A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.

S. Purl, C. Westbrook, J. Bitran, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.

A. A. Ross, T. Moss, B. Brockstein, 1996, Journal of hematotherapy.

Autologous Bone Marrow Transplantation Followed by Involved Field Radiotherapy in Patients with Relapsed or Refractory Hodgkin's Disease.

R. Weichselbaum, J. Moormeier, S. Williams, 1991, Leukemia & lymphoma.

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2004, Bone Marrow Transplantation.

The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product.

A. Oliver, T. Karrison, S. Williams, 1999, Cytotherapy.

Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.

R. Weichselbaum, A. Mundt, H. Halpern, 1994, International journal of radiation oncology, biology, physics.

A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia.

R. Larson, R. Geller, C. Chandler, 1992, Leukemia & lymphoma.

Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.

J. Ultmann, E. Gaynor, S. Williams, 1986, Cancer treatment reports.

Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer.

S. Myers, S. Williams, 1993, Hematology/oncology clinics of North America.

Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease

J. Mehta, S. Trifilio, T. Zembower, 2004, Bone Marrow Transplantation.

Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 109/l neutrophils on 3 consecutive days to define myeloid recovery

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Clinical use of selected and expanded peripheral blood CD34+ cells: a preliminary report of feasibility and safety.

W. Lee, J. Bender, F. Oldham, 1995, Journal of hematotherapy.

Antineoplastic drugs administered during pregnancy.

R. Schilsky, S. Williams, S. Williams, 2000, Seminars in oncology.

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.

R. Mick, T. Gilewski, J. Bitran, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

J. Armitage, J. Fay, J. Klein, 1999, JAMA.

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

J. Armitage, J. Fay, J. Klein, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation.

W. Lee, J. Bender, S. Smith, 1994, Clinical immunology and immunopathology.

Patients at increased risk for late engraftment after transplantation: a novel method for their identification.

R. Mick, S. Williams, J. Bitran, 1990, Bone marrow transplantation.

Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.

E. Shpall, U. Gehling, K. Helm, 1997, Experimental hematology.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy: clinical results in patients with contaminated or hypocellular bone marrow.

R. Geller, S. Myers, S. Williams, 1992, Journal of hematotherapy.

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

J. Winter, S. Singhal, J. Mehta, 2005, Bone Marrow Transplantation.

CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit

J. Winter, S. Singhal, J. Mehta, 2001, Bone Marrow Transplantation.

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2003, Bone Marrow Transplantation.

Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.

J G Bender, F Oldham, T. Zimmerman, 1996, Blood.

Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia

A. Kumari, L. Faulkner, S. Ramprakash, 2017, Bone Marrow Transplantation.

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

J. Winter, S. Singhal, J. Mehta, 2009, Bone Marrow Transplantation.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer

M. Horowitz, R. Gale, H. Lazarus, 2003, Bone Marrow Transplantation.

Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry.

R. Ghalie, D. V. Van Epps, M. J. Kennedy, 1995, Experimental hematology.

High‐Dose Chemotherapy with Autologous Stem Cell Rescue for Breast Cancer: Yesterday, Today and Tomorrow

S. Williams, B. Brockstein, 1996, Stem cells.

The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

S. Williams, 1990, Seminars in oncology.

Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.

R. Larson, R. Geller, C. Chandler, 1992, Bone marrow transplantation.

Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.

D. Hallahan, R. Weichselbaum, A. Mundt, 1995, International journal of radiation oncology, biology, physics.

Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis.

R. Larson, M. L. Le Beau, J. Vardiman, 1986, Blood.

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G‐CSF in patients with lymphoma

T. Zimmerman, R. Mick, G. Michelson, 1999, Journal of clinical apheresis.

Guillain-Barré syndrome after autologous bone marrow transplantation for breast cancer: report of two cases.

S. Myers, S. Williams, 1994, Bone marrow transplantation.

Comparison of three mobilization regimens for peripheral blood progenitor cell rescue after high dose chemotherapy.

W. Lee, J. Bender, S. Williams, 1994, Progress in clinical and biological research.

Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF).

D. Williams, M. Loudovaris, W. Lee, 1997, Journal of hematotherapy.

High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma.

S. Williams, L. Kaminer, J. Beschorner, 1989, Bone marrow transplantation.

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

A. Rademaker, L. Gordon, J. Winter, 2006, Annals of Oncology.

Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients.

H. W. Lee, S. Smith, S. Williams, 1999, Cytotherapy.

Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors.

S. Williams, T. Zimmerman, 1998, Cytokines, cellular & molecular therapy.

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.

R. Mick, W. Lee, J. Bender, 1995, Bone marrow transplantation.

Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow.

L. Lum, P. Maples, S. Smith, 1993, Experimental hematology.

Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer.

M. Cobleigh, J. Wolter, R. Ghalie, 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.

H. Lazarus, B. Cooper, M. Campion, 1995, Bone Marrow Transplantation.

Isolated/primary CNS relapse in women in remission after ABMT for metastatic breast cancer.

S. Williams, E. Ellis, 1992, Bone marrow transplantation.

High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies.

J. Moormeier, S. Williams, L. Kaminer, 1990, Journal of the National Cancer Institute.

A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.

J. Moormeier, S. Williams, L. Kaminer, 1990, Bone Marrow Transplantation.

The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

S. Williams, G. Laport, 1998, Seminars in oncology.